Cannabis Landing Page Compliance for Telehealth Ads

8 August 2026

Your landing page decides whether a paid campaign succeeds, and in the regulated cannabis space it often decides something earlier: whether your ad runs at all. Cannabis landing page compliance is not a technical afterthought. It is your entry ticket to paid channels. One non-compliant page can trigger a disapproval, and repeated violations can suspend the entire ad account.

Telehealth brands often underestimate this. They polish ad copy and bids while the destination page is the real gatekeeper. Google and Meta review the landing page as strictly as the ad, sometimes more strictly.

This article covers what a cannabis telehealth landing page must include, where the legal lines run in the US, UK and Canada, and which issues typically fail ad review. Treat it as the current state of research, not legal advice.

Why cannabis landing page compliance decides your ad review

Platforms review your destination, not just your creative. Google Ads, Meta and endemic networks match your copy, offer and landing page against their healthcare policies. If the page does not fit, the ad is rejected. Repeated violations can suspend your whole advertising account.

Telemedicine in cannabis adds a second layer: regulators and competitors. A page that passes ad review can still breach national law. Both layers have to line up.

Prescription rules: the legal frame in the US, UK and Canada

The picture differs sharply by country. In the US, cannabis remains federally restricted and rules vary state by state, while telehealth for prescription products runs through platform certification. In the UK, medical cannabis is a specialist, prescription-only route, and advertising prescription-only medicines to the public is prohibited, so consumer-facing promotion of a specific Rx therapy is off the table. In Canada, adult-use cannabis is legal under the Cannabis Act, yet promotion rules are strict: no appeal to youth, no lifestyle glamour, no false impressions.

The DACH market is a useful warning. Germany's Federal Court of Justice confirmed in March 2026 that advertising medical cannabis treatments to consumers breaches the drug advertising act. The lesson travels: inform, do not manufacture demand. Check every target region on its own.

The must-have elements of a compliant landing page

Regardless of market, platforms and certifiers expect a baseline. Work through these before any campaign goes live:

Secure connection and transparency: HTTPS, an accessible privacy policy in the footer, and a working contact method.
Clear provider identity: who runs the service, their licensing and credentials, and the regions where the offer is available.
Factual language: no health claims, no absolutes like "cure," "miracle" or "guaranteed," no before-and-after promises.
No public Rx promotion: in restrictive markets, do not push a prescription substance to lay consumers to drive demand.
Privacy by design: no health data in URL parameters, no remarketing based on inferred conditions, and consent handling that fits local law such as GDPR and TCF in the EU.
Message match: ad, keyword and landing page point to the same offer. A gap between ad and destination is a frequent rejection reason.

For telemedicine and prescription-related offers, Google requires LegitScript certification in several countries before ads can serve at all. LegitScript reviews licensing, prescribing processes and, explicitly, your landing pages and disclaimers. Certification is per domain and is recognized for telemedicine in markets including the US, Canada, France and Sweden. It is not a shortcut around local law: in the DACH region, consumer Rx promotion stays restricted whatever a platform allows.

Common mistakes that fail ad review

Sending the ad to a homepage instead of a dedicated page that matches search intent.
Symptom or indication lists that promote a specific prescription product.
A missing or hidden privacy policy, or no clear provider identification.
Forms that collect health data without a lawful basis or proper security.
Mobile load times over three seconds, which drag down quality score and conversions.

Each of these is avoidable. A short compliance check before launch costs minutes. An account suspension costs weeks.

Conclusion

Cannabis landing page compliance is the foundation of every paid telehealth campaign, not an afterthought. Align platform rules and national law from the start, and you pass ad review, protect your account and build trust. Rules differ by country and platform and change quickly, so treat this as the current state of research, not legal advice. When in doubt, review each target region separately and have sensitive offers checked by counsel. The best ad is worthless if the page behind it fails.